Title : Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.

Pub. Date : 2019 Nov

PMID : 31644442






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVES: The discovery of tyrosine kinase inhibitors (TKI) has remarkably improved the clinical course of patients with non-small cell lung cancer driven by Epidermal Growth Factor Receptor (EGFR) mutations. Tyrosine epidermal growth factor receptor Homo sapiens
2 OBJECTIVES: The discovery of tyrosine kinase inhibitors (TKI) has remarkably improved the clinical course of patients with non-small cell lung cancer driven by Epidermal Growth Factor Receptor (EGFR) mutations. Tyrosine epidermal growth factor receptor Homo sapiens